GPT and hepatocellular carcinoma: However, the patients with HCC generally have underlying liver dysfunction before treatment is initiated and this elevation in AST and ALT, indicating possible underlying liver dysfunction, is not sufficiently problematic to cause patients to drop out of the clinical trial and stop therapy.